T cell responses may be feasible for specific antiviral immunotherapies through careful selection and administration of individual IFNα subtypes.
No takes yet. Share an insight, caveat, or question.
Dickow et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: